Eupraxia Pharmaceuticals Inc. (EPRX) Reports 52-Week Data Showing 64% Clinical Remission

Eupraxia reported updated Phase 1b/2a RESOLVE data for EP-104GI in EoE, with 64% of patients in clinical remission over 52 weeks in higher-dose cohorts and histologic improvements observed; no treatment-related SAEs reported. Phase 2b interim data are expected in Dec 2026.Material DetailsContext by…